

Supplementary Table 2: Clinical and pathological characteristics of the HNSCC validation cohort (Bonn)

Primary tumors (PT) n=237 (%)	
Mean age (y) [SD]	62.5 [11.2]
Sex (n=231)	164 (71) male
p16 status (n=231)	27 (11.7) positive
5-year OS from diagnosis (n=218)	140 (64)
Anatomical site (n=231)	
Oral cavity	68 (29.4)
Oropharynx	83 (35.9)
Hypopharynx	20 (8.7)
Larynx	60 (26)
T Stage (n=229)	
T1	64 (27.9)
T2	80 (34.9)
T3	54 (23.6)
T4	31 (13.5)
N Stage (n=227)	
0	115 (50.7)
1	35 (15.4)
2	73 (32.2)
3	4 (1.8)
M Stage (n=231)	
0	222 (96.1)
1	9 (3.9)
Differentiation (n=204)	
Well	9 (4.4)
Moderate	132 (64.7)
Poor	63 (30.9)
Surgery (n=228)	215 (94.3)
Resection (n=188)	
R0	169 (89.9)
R1	14 (7.4)
R2	5 (2.7)
Radiotherapy (n=218)	139 (63.8)
Chemotherapy (n=218)	62 (28.4)
Recurrency (n=197)	60 (30.5)

Recurrent tumors (RT) n=45 (%)	
Mean age (y) [SD]	62.4 [10]
Sex (n=31)	22 (71) male
p16 status (n=31)	5 (16.1) positive
5-year OS from diagnosis (n=27)	7 (25.9)
Anatomical site (n=31)	
Oral cavity	13 (41.9)
Oropharynx	11 (35.5)
Hypopharynx	1 (3.2)
Larynx	6 (19.4)
N Stage (n=27)	
0	19 (70.4)
1	8 (29.6)
M Stage (n=27)	
0	26 (96.3)
1	1 (3.7)
Surgery (n=26)	24 (92.3)
Radiotherapy (n=26)	16 (61.5)
Chemotherapy (n=26)	11 (42.3)
Time between PT and RT (m) [SD] (n=27)	11.6 [5.3]
Radio- +/- chemotherapy between PT and RT (n=29)	18 (62.1)

PT: primary tumor, RT: recurrent tumor, y: year, SD: standard deviation, m: months, OS: overall survival